AXSOME THERAPEUTICS, INC.
At today's price, AXSOME THERAPEUTICS, INC. (AXSM) is priced for today's economics sustained for ~11.2 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
At $250.61 Axsome is a commercial-stage biotech priced on a revenue multiple, not earnings: the price embeds a long ramp to a roughly 36% operating margin sustained for about 12 years, and no valuation family reaches the quote on current numbers. The balance sheet shows a company funding a launch, not in distress. Cash of $305 million against gross debt of $197 million leaves a net cash position, but the business is burning, with a Q1 2026 net loss of $64.5 million as it scales the sales force
Is AXSM overvalued? See what's priced in →
397 institutional managers reported holding AXSM in 13F filings for the quarter ended 2026-03-31. Together they hold about 74% of the company; the top 10 hold 35%. 61 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 3.3M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AXSM's share count grew 36.2% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at AXSM over the trailing three years: 2025: 3 buys totaling $200k. 8 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AXSM's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | -1.5% | -2.7% |
| 2023-11-07 | -3.1% | +43.3% |
| 2024-02-24 | -11.5% | -9.2% |
| 2024-05-07 | +2.9% | +5.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AXSM's latest 8-K filings: 2026-06-09 (items 5.02, 9.01); 2026-06-09 (items 5.07, 9.01); 2026-06-03 (items 8.01, 9.01); 2026-05-04 (items 2.02, 8.01, 9.01); 2026-04-30 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.